<DOC>
	<DOCNO>NCT00072410</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell deliver radioactive tumor-killing substance without harm normal cell . Giving radiolabeled monoclonal antibody directly abdominal cavity may kill tumor cell . PURPOSE : Phase I trial study effectiveness give radiolabeled monoclonal antibody therapy directly abdominal cavity treat patient advanced ovarian epithelial cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Treating Patients With Advanced Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety maximum tolerate dose intraperitoneal yttrium Y 90 monoclonal antibody Hu3S193 ( Y90 MOAB Hu3S193 ) patient advanced ovarian epithelial cancer . Secondary - Determine localization whole body abdominal clearance drug patient use indium In 111 monoclonal antibody Hu3S193 gamma camera imaging . - Determine serum pharmacokinetics Y90 MOAB Hu3S193 patient use gamma well count . - Determine antibody response patient treated drug . OUTLINE : This dose-escalation study yttrium Y 90 monoclonal antibody Hu3S193 ( Y90 MOAB Hu3S193 ) . Patients receive intraperitoneal ( IP ) technetium Tc 99m sulfur colloid undergo abdominal imaging day 1 . Provided distribution technetium Tc 99m sulfur colloid deem adequate , patient receive IP Y90 MOAB Hu3S193 IP indium In 111 monoclonal antibody Hu3S193 ( image ) 30 minute day 1 . Within 3-5 hour antibody administration , patient undergo whole body image single-photon emission-computed tomography ( SPECT ) image abdomen pelvis . Cohorts 3-6 patient receive escalate dos Y90 MOAB Hu3S193 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month least 2 year every 6 month 5 year . PROJECTED ACCRUAL : A maximum 42 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonmucinous ovarian adenocarcinoma Persistent recurrent intraperitoneal disease platinum/taxanebased therapy stage III ovarian cancer No active parenchymal disease ( stage IV ) No symptomatic extraabdominal metastases No known CNS tumor involvement PATIENT CHARACTERISTICS : Age Any age Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No bleeding disorder Hepatic Bilirubin great 2.0 mg/dL AST ALT great 2.5 time upper limit normal Renal Creatinine great 2.0 mg/dL Cardiovascular LVEF least 50 % No New York Heart Association class III IV heart disease No clinically significant arrhythmia ECG No evidence prior myocardial infarction Pulmonary FEV_1 least 60 % predict FVC least 60 % predicted Diffusion capacity least 55 % predict Other Not pregnant nursing Negative pregnancy test No serious illness would preclude study participation No serious infection require antibiotic No chronic inflammatory bowel disease Human antimouse antibody negative PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior biologic therapy More 4 week since prior immunotherapy No prior murine monoclonal antibody therapy Chemotherapy See Disease Characteristics More 4 week since prior chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No immunosuppressive therapy 30 day administration yttrium Y 90 monoclonal antibody Hu3S193</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
</DOC>